BridgeBio historically holds educational webinars weeks before releasing key data. Investors should view the upcoming event on its achondroplasia drug as a way to frame the future data readout, not as the readout itself. Data is not expected until at least February.
By elevating the riskier peak VO2 endpoint to a co-primary with KCCQ, Cytokinetics only needs to hit one for the trial to succeed. This clever design increases the probability of a positive top-line result for its non-obstructive hypertrophic cardiomyopathy indication, a sizable market.
The market has broadly punished vaccine stocks, but the US administration's negative focus has been primarily on COVID-19 vaccines. In contrast, recent HHS guidance specifically recommended pneumococcal vaccines for all children, suggesting a positive macro environment for companies like Vaxite.
Similar to how Gilead was viewed before its stock surge, Biogen is seen as a sleepy big-cap with a declining core business. However, it has several underappreciated near-term catalysts in Alzheimer's (tau program), SLE, and lupus that could re-rate the stock.
While efficacy seems similar to Bristol's Kamsiyos, MYCorzo's key advantage is being less resource-intensive for doctors. With fewer required echos, a better drug interaction profile, and faster titration, it simplifies physician workflow, which could drive adoption and market share over time.
In renal cell carcinoma, Arcus's casdadafin demonstrated a 12.2-month median PFS as a monotherapy. This nearly matches the 13.7-month PFS of Merck's competitor drug, belzutafan, when used in combination. This suggests Arcus's upcoming combination data could be substantially superior.